Bulk Pharmaceutical API Sources for VASCEPA

Bulk Pharmaceutical API Sources for VASCEPA

Vendor	Vendor Homepage	Vendor Sku	API Url
TCI (Tokyo Chemical Industry)		E0442
Molport		MolPort-006-393-913
Oakwood Products		035939
TCI (Tokyo Chemical Industry)		E0853
Finetech Industry Limited		FT-0667829
AKos Consulting & Solutions		AKOS025295847
BOC Sciences		86227-47-6

Bulk Active Pharmaceutical Ingredient (API) Sources for Vascepa

Last updated: July 28, 2025

Introduction

Vascepa (icosapent ethyl) is a purified form of eicosapentaenoic acid (EPA), an omega-3 fatty acid utilized primarily for reducing triglyceride levels and mitigating cardiovascular risk. Its efficacy and safety are closely tied to the quality of the active pharmaceutical ingredient (API). The sourcing of bulk API is a critical factor in pharmaceutical manufacturing, affecting regulatory compliance, product consistency, and market competitiveness. This article examines the primary sources and suppliers of the API used in Vascepa, emphasizing their global positioning, manufacturing standards, and strategic significance to pharmaceutical companies.

Overview of API Sourcing in Vascepa Production

The quality of icosapent ethyl hinges dramatically on the integrity of its raw material—EPA-rich fish oil derivatives. API sourcing involves multiple stages, including extraction, purification, and synthesis, often occurring in specialized facilities adhering to Good Manufacturing Practices (GMP). Suppliers range from integrated seafood-based API producers to chemical synthesis firms, each with distinct advantages.

Major API Suppliers for Vascepa

1. Cephalon (Teva Pharmaceutical Industries)

Cephalon, the original developer of Vascepa, historically managed its API sourcing through vertically integrated production and contracted manufacturing organizations (CMOs). Prior to its acquisition by Teva, Cephalon maintained exclusive rights to supply the API, primarily sourcing EPA from well-established fish oil extraction operations. Post-acquisition, Teva inherited these supply chains, emphasizing GMP compliance and quality assurance.

2. Commercial API Producers of Omega-3 Ethyl Esters

a. Pronova Biocare (now part of Evonik Industries)

Pronova's expertise in omega-3 fatty acids dates back decades, originally specializing in pharmaceutical-grade fish oil concentrates. Their facilities in Norway and Denmark produce high-purity omega-3 ethyl esters compliant with pharmacopeial standards, notably the United States Pharmacopeia (USP) and European Pharmacopoeia (Ph. Eur.).

b. Kaustubha Pharma

An emerging supplier based in India, Kaustubha Pharma offers bulk API manufacturing for pharmaceutical applications. Their GMP-certified facilities focus on omega-3 ethyl esters, leveraging advanced purification techniques that meet international standards.

c. Aker BioMarine

A Norwegian biotech company with a focus on sustainable krill oil extraction, Aker BioMarine supplies omega-3 API with an emphasis on purity and environmental impact. Its proprietary extraction processes yield high-concentration EPA products suitable for pharmaceutical APIs.

d. Croda International

A global specialty chemicals company, Croda supplies omega-3 concentrates derived from fish oils. Their manufacturing facilities operate under strict GMP guidelines, and their products are used as ingredients in pharmaceutical formulations, including APIs.

3. Contract Manufacturing Organizations (CMOs)

Numerous CMOs globally provide custom synthesis and API manufacturing services, including:

• BASF Deutschland GmbH: Offers pharmaceutical-grade omega-3 ethyl esters with high purity and batch consistency.

• Lonza Group: Provides API synthesis and purification services, ensuring compliance with regulatory standards.

• Catalent Pharma Solutions: Specializes in lipid-based APIs, offering tailored manufacturing processes for EPA derivatives.

These CMOs often serve as strategic partners, ensuring supply chain resilience and regulatory compliance.

Emerging Sources and Strategic Considerations

In recent years, biotechnology firms focusing on microbial fermentation or recombinant synthesis to produce EPA have entered the stage, promising scalable and sustainable alternatives to fish oil extraction. Companies like Corbion and DSM are investing in biotechnological approaches, which could impact the API sourcing landscape in the future, aligning with sustainability and supply security.

Quality and Regulatory Standards

API suppliers for Vascepa must meet stringent regulatory standards. The FDA mandates compliance with current Good Manufacturing Practices (cGMP), sourcing from facilities validated for purity, stability, and consistency. Certificates of Analysis (CoA), batch records, and quality certifications are prerequisites for pharmaceutical-grade API procurement.

Supply Chain Implications

Reliance on a limited number of suppliers introduces potential risks, including geopolitical instability, raw material scarcity, and regulatory disruptions. Consequently, pharmaceutical firms often diversify their API sourcing portfolio to mitigate these risks, engaging multiple suppliers across regions such as North America, Europe, and Asia.

Geopolitical and Market Dynamics

• North America and Europe: Historically dominated by companies like Pronova and European biotech firms, these regions emphasize stringent quality controls and transparency.

• Asia-Pacific: India and China host a growing number of API manufacturers, driven by cost advantages and expanding production capacity, albeit with ongoing challenges around quality assurance and regulatory oversight.

Conclusion

The API landscape for Vascepa is characterized by a combination of established European suppliers, North American innovators, and rapidly expanding Asian manufacturers. Ensuring API quality and supply stability involves navigating complex regulatory environments, technological innovations, and geopolitical factors. As the demand for EPA-based therapies grows, strategic partnerships with reliable API sources will be critical for pharmaceutical companies aiming to sustain high-quality Vascepa production.

---

Key Takeaways

• Major suppliers include Pronova (Evonik), Aker BioMarine, and several CMOs like BASF and Lonza, with sourcing primarily from high-quality fish oil extraction and purification processes.

• Emerging biotechnological methods for EPA production offer sustainable alternatives and could reshape API sourcing in the coming years.

• Regulatory compliance, particularly with cGMP standards, remains non-negotiable for API suppliers in the pharmaceutical sector.

• Supply chain diversification is vital to mitigate risks related to geopolitical instability, raw material scarcity, and regulatory changes.

• Geographical considerations influence API quality, cost, and supply security, with North America and Europe maintaining strict quality standards compared to the rapidly growing Asian API market.

---

FAQs

1. What are the primary raw materials used in API production for Vascepa?
The raw material mainly comprises EPA derived from marine sources—primarily fish oils—extracted and purified to produce pharmaceutical-grade icosapent ethyl.

2. How do regulatory standards impact API sourcing for Vascepa?
Regulatory frameworks like the FDA and EMA require API suppliers to meet cGMP standards, ensuring purity, consistency, and traceability, which directly influence supplier selection and quality assurance processes.

3. Are there alternative sources of EPA besides fish oil for API manufacturing?
Yes. Biotechnology companies are exploring microbial fermentation and recombinant DNA technologies to synthesize EPA, offering sustainable and scalable alternatives to traditional fish oil extraction.

4. How do geopolitical factors influence API supply for Vascepa?
Geopolitical issues can disrupt supply chains, especially when APIs are sourced from regions with political instability or trade restrictions. Diversification and supply chain resilience strategies are crucial for uninterrupted production.

5. What future trends could impact the API sourcing landscape for Vascepa?
Advancements in synthetic biology, sustainable harvesting practices, and increased regulatory scrutiny are likely to reshape sourcing strategies, emphasizing quality, sustainability, and supply stability.

---

References

[1] U.S. Food and Drug Administration. (2022). Vascepa (icosapent ethyl) prescribing information.
[2] Evonik Industries. (2021). Omega-3 fatty acids manufacturing and certification standards.
[3] Aker BioMarine. (2022). Sustainable omega-3 production processes.
[4] BASF. (2023). API manufacturing capabilities for lipid-based APIs.
[5] European Pharmacopoeia. (2022). Standards for omega-3 fatty acid purity and API specifications.*